Catalog #CP253

RecombiMAb anti-mouse CD44

Clone KM201-CP253
Reactivities Mouse
Applications in vivo CD44-HA blockade *
in vitro CD44-HA blockade *
ex vivo CD44-HA blockade *
in vitro organoids/organ-on-chip *
in vitro functional assay*
Flow cytometry*
Immunohistochemistry- paraffin*
Immunohistochemistry-frozen*
Immunofluorescence*
Immunoprecipitation*
Western blot*
*reported for the original KM201 antibody (rat IgG1 kappa)
Isotype Mouse IgG2a, κ
(Switched from Rat IgG1, κ)

$560.00 - $14,859.50

$560.00 - $14.00

Choose an Option...
  • 100 mg - $14,859.50
  • 50 mg - $10,614.00
  • 25 mg - $7,581.50
  • 5 mg - $2,170.50
  • 1 mg - $560.00
  • Custom Amount (Quotes Only)
In stock
Only %1 left
US Customers - Order within 3 hours, 19 minutes to receive by November 19.

Product Description

The KM201-CP253 antibody is a recombinant mouse IgG2a k isotype chimeric variant that retains the same antigen-binding regions as KM201 (rat IgG1κ), which is well established for recognizing mouse CD44. Unlike other anti-CD44 clones such as IM7, which recognizes an epitope outside the hyaluronan (HA)-binding domain, and KM703, which does not inhibit CD44–HA binding, the KM201 antibody is well known for direct binding to an epitope near or within the N-terminal HA-binding domain. This specific binding is often correlated with its HA-CD44 signaling blockade efficacy. CD44, also known as Hermes, HCAM, and Pgp-1, is a cell surface glycoprotein that is widely expressed on leukocytes and many endothelial and mesenchymal cells, with expression varying by cell type and physiological or pathological state. CD44 is involved in cell adhesion, migration, and interactions with the extracellular matrix (ECM), and it is involved in lymphocyte activation, recirculation and homing, and hematopoiesis. CD44’s principal ligand is HA, but it also interacts with proteins such as osteopontin and collagens and can serve as a cell-surface docking molecule for certain MMPs. CD44-dependent interactions play an important role in inflammation and tissue organization. The original KM201 antibody has been used to inhibit CD44–HA interactions in experimental studies and has been reported to reduce arthritis severity in mouse models, supporting evaluation of KM201-CP253 in research involving CD44-mediated adhesion and inflammation. From an engineering perspective, the KM201-CP253 antibody retains the exact variable domain sequences of KM201, while its constant region has been switched to mouse IgG2a, κ, for better compatibility with murine models. Species-matched chimeric antibodies support repeat and long-term dosing studies by reducing anti-drug antibody (ADA) responses that can accelerate antibody clearance, compromise sustained target neutralization, and confound interpretation of in vivo efficacy and safety findings. The highly controlled sequence and lack of genetic drift in recombinant antibodies provide more reliable and reproducible results than hybridoma-derived antibodies. In the case of KM201-CP253, the mouse IgG2a Fc makes it a logical choice for evaluating Fcγ receptor–mediated depletion of CD44-expressing cells in vivo and for distinguishing cell-clearance effects from HA-binding blockade. However, the functional activity and Fc-dependent effects of KM201-CP253 should be established experimentally, because the parental KM201’s findings are a rationale for evaluating KM201-CP253, not proof of its functional equivalence.

Specifications

Isotype Mouse IgG2a, κ
Recommended Isotype Control(s) RecombiMAb mouse IgG2a isotype control, unknown specificity
Recommended Dilution Buffer InVivoPure pH 7.0 Dilution Buffer
Immunogen Bone marrow-derived stromal cell clone BMS2
Reported Applications in vivo CD44-HA blockade *
in vitro CD44-HA blockade *
ex vivo CD44-HA blockade *
in vitro organoids/organ-on-chip *
in vitro functional assay*
Flow cytometry*
Immunohistochemistry- paraffin*
Immunohistochemistry-frozen*
Immunofluorescence*
Immunoprecipitation*
Western blot*
*reported for the original KM201 antibody (rat IgG1 kappa)
Formulation PBS, pH 7.0
Contains no stabilizers or preservatives
Endotoxin ≤0.5EU/mg (≤0.0005EU/μg)
Determined by LAL assay
Aggregation <5%
Determined by SEC
Purity ≥95%
Determined by SDS-PAGE
Sterility 0.2 µm filtration
Production Purified from mammalian cell supernatant in an animal-free facility
Purification Protein G
Molecular Weight 150 kDa
Murine Pathogen Tests Ectromelia/Mousepox Virus: Negative
Hantavirus: Negative
K Virus: Negative
Lactate Dehydrogenase-Elevating Virus: Negative
Lymphocytic Choriomeningitis virus: Negative
Mouse Adenovirus: Negative
Mouse Cytomegalovirus: Negative
Mouse Hepatitis Virus: Negative
Mouse Minute Virus: Negative
Mouse Norovirus: Negative
Mouse Parvovirus: Negative
Mouse Rotavirus: Negative
Mycoplasma Pulmonis: Negative
Pneumonia Virus of Mice: Negative
Polyoma Virus: Negative
Reovirus Screen: Negative
Sendai Virus: Negative
Theiler’s Murine Encephalomyelitis: Negative
Storage This product should be stored at the stock concentration at 4°C. Do not freeze.
Need a Custom Formulation? See All Antibody Customization Options

Application References

  • in vivo CD44-HA blockade in vitro functional assay
    Mikecz K, Dennis K, Shi M, Kim JH (1999). "Modulation of hyaluronan receptor (CD44) function in vivo in a murine model of rheumatoid arthritis." Arthritis Rheum 42(4):659-68.

    To determine how in vivo modulation of CD44 function by antibodies influences disease severity in a murine model of rheumatoid arthritis. Mice with proteoglycan (PG)-induced arthritis were subjected to systemic treatment with 3 different monoclonal antibodies against CD44. Joint swelling and serum levels of hyaluronan (HA) and soluble CD44 (sCD44) were monitored. Inflammatory leukocyte infiltration in the joints, cell surface CD44 expression, and leukocyte adhesion to HA were compared. The effects of anti-CD44 treatment on the immune status of arthritic animals were also determined. Antibody IRAWB14, which enhances HA binding, aggravated the inflammatory symptoms, while KM201, which blocks ligand binding, reduced the severity of arthritis. The most effective suppression of inflammation was noted upon treatment with antibody IM7, whose epitope lies outside the HA binding domain of CD44. Serum levels of sCD44 increased, and HA levels decreased, in response to IM7. KM201 and IM7 treatment reduced, but IRAWB14 treatment enhanced, the adhesion of leukocytes to HA. However, these antibodies had little effect on PG-specific immune responses. Each antibody acted in vivo by virtue of its combined effects on CD44-HA binding and CD44 shedding. The dramatic reduction in arthritis severity effected by IM7 treatment was associated with extensive shedding of cell surface CD44 molecules. Loss of CD44 appears to be a major factor in preventing CD44- and HA-dependent cell-matrix interactions at the inflammatory site. Our study indicates a critical role for CD44 in the pathology of joint inflammation and reveals a unique mechanism of receptor down-regulation, which can be used therapeutically.

  • in vivo CD44-HA blockade
    Crow AR, Song S, Suppa SJ, Ma S, Reilly MP, Andre P, McKenzie SE, Lazarus AH (2011). "Amelioration of murine immune thrombocytopenia by CD44 antibodies: a potential therapy for ITP?" Blood 117(3):971-4.

    To explore the potential for monoclonal antibodies as a treatment for immune thrombocytopenia (ITP) and to further explore their mechanisms of action, we tested 8 monoclonal CD44 antibodies in murine ITP and found 4 antibodies that could successfully ameliorate ITP; 2 of these antibodies function at a full 3-log fold lower dosage compared with IVIg. Further characterization of the 2 most successful antibodies (5035-41.1D and KM114) demonstrated that, similar to IVIg: (1) the presence of the inhibitory IgG receptor FcγRIIB was required for their ameliorative function, (2) complement-deficient mice responded to anti-CD44 treatment, and (3) human transgenic FcγRIIA-expressing mice also responded to the CD44 therapeutic modality. Dissimilar to IVIg, the Fc portion of the CD44 antibody was not required. These data demonstrate that CD44 antibodies can function therapeutically in murine ITP and that they could potentially provide a very-low-dose recombinant therapy for the amelioration of human ITP.

  • in vitro CD44-HA blockade Immunoprecipitation Flow Cytometry
    Miyake K, Medina KL, Hayashi S, Ono S, Hamaoka T, Kincade PW (1990). "Monoclonal antibodies to Pgp-1/CD44 block lympho-hemopoiesis in long-term bone marrow cultures." J Exp Med 171(2):477-88.

    A new panel of mAbs was prepared to a stromal cell line known to support lymphocytes in Whitlock-Witte type long-term bone marrow cultures. These antibodies were then screened with a cell adhesion assay and four were selected that inhibited the binding of B lineage cells to stromal cell monolayers. Immunofluorescent and biochemical analyses revealed that these new antibodies detected epitopes of the previously described Pgp-1/CD44 antigen complex. Addition of Pgp-1/CD44 antibodies to Dexter-type long-term bone marrow cultures completely prevented emergence of myeloid cells and they also blocked lymphocyte growth in Whitlock-Witte type cultures. mAbs MEL-14, LFA-1, and CD45R did not inhibit under the same conditions and there was no apparent relationship to Ig isotype. Adherent layers in treated cultures were not unusual in terms of morphology and the antibodies did not affect factor-dependent replication of lymphoid or myeloid progenitor cells. Therefore, the mechanism of inhibition may not involve direct toxicity to precursors or microenvironmental elements. Previous studies in humans and mice have implicated Pgp-1/CD44-related glycoproteins in the migration of peripheral lymphoid cells, as well as interactions of cells with the extracellular matrix. These findings suggest that they may also be critical for formation of lymphoid and myeloid cells within bone marrow.

  • in vivo CD44-HA blockade
    Katoh S, Matsumoto N, Kawakita K, Tominaga A, Kincade PW, Matsukura S (2003). "A role for CD44 in an antigen-induced murine model of pulmonary eosinophilia." J Clin Invest 111(10):1563-70.

    Previous studies established that IL-5-producing CD4(+) T cells play a pivotal role in allergic respiratory inflammation. It was also reported that CD4(+) T cells express higher levels of CD44 in the airway than in peripheral blood of patients with allergic respiratory diseases. We have used experimental pulmonary eosinophilia induced in mice by Ascaris suum (Asc) extract to investigate the role of CD44 in the development of allergic respiratory inflammation. Intraperitoneal administration of anti-CD44 mAb prevented both lymphocyte and eosinophil accumulation in the lung. Anti-CD44 mAb also blocked antigen-induced elevation of Th2 cytokines as well as chemokines (CCL11, CCL17) in bronchoalveolar lavage fluid (BALF). Treatment with anti-CD44 mAb inhibited the increased levels of hyaluronic acid (HA) and leukotriene concentrations in BALF that typically result from antigen challenge. Anti-CD44 mAb also blocked antigen-induced airway hyperresponsiveness. An anti-CD44 mAb (IM7) inhibited the HA-binding ability of splenocytes associated with decreased levels of CD44. Soluble CD44 levels in serum were increased in Asc-challenged IM7-treated mice, but not in KM201-treated mice, compared with Asc-challenged rat IgG-treated mice. Ab's that block CD44-HA binding reduced allergic respiratory inflammation by preventing lymphocyte and eosinophil accumulation in the lung. Thus, CD44 may be critical for development of allergic respiratory inflammation.

Product FAQs

Additional Formats

  1. Catalog #CP254
    RecombiMAb anti-mouse CD44 (LALA-PG) Read more